#### Brilliant Violet 750™ anti-human HLA-DR

Catalog # / 2138355 / 25 tests

Size: 2138360 / 100 tests

Clone: L243

Isotype: Mouse IgG2a, κ

Human, Non-human primate, Other Reactivity:

**Preparation:** The antibody was purified by affinity

chromatography and conjugated with Brilliant Violet 750™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 750™


and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

BSA (origin USA).

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with CD19 FITC and HLA-DR (Clone L243) Brilliant Violet 750™ (left) or CD19 FITC only (right).

### **Applications:**

Flow Cytometry **Applications:** 

Recommended Each lot of this antibody is quality control tested by immunofluorescent **Usage:** 

staining with flow cytometric analysis. For flow cytometric staining, the

suggested use of this reagent is 5 μl per million cells in 100 μl staining volume

or 5 µl per 100 µl of whole blood.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

**Application** Notes: The L243 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross react with HLA-DP and HLA-DQ. Clone L243 binds a conformational epitope on HLA-DRα which depends on the

correct folding of the  $\alpha\beta$  heterodimer.<sup>19</sup>

Additional reported applications (for the relevant formats) include: immunoprecipitation<sup>8</sup>, Western blotting<sup>8</sup>, in vitro blocking of mixed lymphocyte reactions  $^{9,10}$ , depeletion of MHC class II cells  $^{\overline{7}}$ , and immunohistochemical staining of acetone-fixed frozen sections<sup>4,5</sup>.

# Application References:

- 1. Brodsky F. 1984. Immunogenetics 19:179.
- 2. Robbins P, et al. 1987. Human Immunol. 18:301.
- 3. Stites D, et al. 1986. Clin. Immunol. Immunopathol. 38:161.
- 4. Warnke R, et al. 1980. J. Histochem. Cytochem. 28:771. (IHC)
- 5. Engleman E, et al. 1981. P. Natl. Acad. Sci. USA 78:1791. (IHC)
- 6. Zipf T, et al. 1981. Cancer Res. 41:4786.
- 7. Goodier M, et al. 2000. J. Immunol. 165:139. (Depletion)
- 8. Esser M, et al. 2001. J. Virol. 75:6173. (IP, WB)
- 9. Kalka-Moll WM, et al. 2002. J. Immunol. 169:6149. (Block)
- 10. Wang RF, et al. 1999. Science 284:1351. (Block)
- 11. Zaba LC, et al. 2007. J. Exp. Med. 204:3183. PubMed
- 12. Fujita H, et al. 2009. P. Natl. Acad. Sci. USA 106:21795. PubMed
- 13. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
- 14. Goncalves RM, et al. 2010. Infect. Immun. 78:4763. PubMed
- 15. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- 16. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
- 17. Stein R, et al. 2011. Leuk. Lymphoma 52:273.
- 18. Galkowska H, et al. 1996. Vet. Immunol. Immunopathol. 53:329.
- 19. Moro M, et al. 2005. BMC Immunol. 6:24.
- 20. Lauterbach N, et al. 2014. Mol Immunol. 59:19. PubMed

#### **Description:**

HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD  $\alpha$  (heavy) chain and a 27 kD  $\beta$  (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4 $^+$  T cells.

## Antigen References:

- 1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177.
- 2. Terstappen L, et al. 1990. J. Leukocyte Biol. 48:138.
- 3. Edwards JA, et al. 1986. J. Immunol. 137:490.
- 4. van Es A, et al. 1984. Transplantation 37:65.
- 5. O'Doherty U, et al. 1994. Immunology 82:487.
- 6. Thomas R, et al. 1994. J. Immunol. 153:4016.
- 7. Grouard G, et al. 1996. Nature 384:364.